AIM Vaccine Co., Ltd.

Direct answer

AIM Vaccine Co., Ltd. is publicly traded on HKSE under the ticker 6660.HK.

Operating within the People's Republic of China, AIM Vaccine Co., Ltd. specializes in the entire lifecycle of human vaccine products, encompassing their discovery, production, and market introduction. Among its current developments, the company is advancing Bivalent Delta-Omicron BA.5 mRNA and Monovalent Omicron BA.5 mRNA vaccine candidates for COVID-19, both currently undergoing Phase III clinical trials. Its...

Can you invest in AIM Vaccine Co., Ltd.?

Yes. AIM Vaccine Co., Ltd. is publicly traded on HKSE under the ticker 6660.HK.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for AIM Vaccine Co., Ltd.

Detailed equity research is provided by MarketSnap.